Anti-CD20 Monoclonal Antibodies Market Growth Supported by Key Drivers, Expected to Hit $12.05 Billion by 2029
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Are the Key Growth Indicators and Market Expansion Estimates for the Anti-CD20 Monoclonal Antibodies Market Through 2029?
The anti-CD20 monoclonal antibodies market size has grown strongly in recent years. It will grow from $8.33 billion in 2024 to $9.00 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to the rising prevalence of B-cell malignancies, growing adoption in autoimmune disease treatments, increasing FDA and EMA approvals of novel anti-CD20 therapies, and a growing geriatric population globally.
The anti-CD20 monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.05 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing strategic collaborations and licensing deals, expanding application in combination therapies, rising incidence of relapsed or refractory cases, increasing healthcare expenditure and access in emerging markets, and growing biosimilar development and approvals. Major trends in the forecast period include advancements in monoclonal antibody engineering, integration of anti-CD20 antibodies into combination therapies, technology-driven personalization of cancer therapies, developments in subcutaneous and long-acting formulations, and advancements in bispecific and next-generation antibodies.
Get your free report sample today:
Which Core Market Drivers Are Influencing the Development of the Anti-CD20 Monoclonal Antibodies Market?
The growing autoimmune diseases are expected to propel the growth of the anti-CD20 monoclonal antibodies market going forward. Autoimmune diseases occur when the immune system wrongly identifies the body’s cells as threats and launches an attack against them. Autoimmune diseases are rising due to growing exposure to environmental pollutants, which can impair immune regulation and trigger attacks on the body’s tissues. Anti-CD20 monoclonal antibodies treat autoimmune diseases by eliminating B cells contributing to autoantibody production and inflammation. They help regulate the immune response and reduce disease symptoms. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government organization, in 2022, an estimated 514,000 people (2.0%) in Australia were living with rheumatoid arthritis, a systemic autoimmune disorder, with 2.5% of females and 1.6% of males affected. Therefore, the growing number of autoimmune diseases is driving the growth of the anti-CD20 monoclonal antibodies market.
How Is the Anti-CD20 Monoclonal Antibodies Market Structured Across Its Key Segment Categories?
The anti-cd20 monoclonal antibodies market covered in this report is segmented –
1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications
5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users
Subsegments:
1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux
2) By Obinutuzumab: Gazyva, Biosimilar Candidates
3) By Ofatumumab: Arzerra, Kesimpta
4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab
What Are the Key Industry Trends Driving Growth in the Anti-CD20 Monoclonal Antibodies Market?
Major companies operating in the anti-CD20 monoclonal antibody market are focusing on developing advanced products such as obinutuzumab to target resistant or relapsed B-cell malignancies more effectively. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody designed to target and destroy CD20-positive B cells involved in certain blood cancers and autoimmune diseases. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced that the US Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for the treatment of lupus nephritis. It is based on positive results from the Phase III REGENCY study showing improved complete renal response (CRR) when combined with standard therapy versus standard therapy alone. It marks Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to demonstrate such benefit in lupus nephritis, a severe inflammation caused by lupus that can lead to kidney failure.
Who Are the Principal Market Leaders in the Anti-CD20 Monoclonal Antibodies Market?
Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH
Get the detailed anti-cd20 monoclonal antibodies market report today
Which Regions Are Expected to Record the Strongest CAGR in the Anti-CD20 Monoclonal Antibodies Market?
North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment